Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer
Memorial Sloan Kettering, Fox Chase Cancer Center, Johns Hopkins Medical Center
The purpose of this study is to find the best dose of the investigational drugs guadecitabine and mocetinostat to be given safely and effectively with pembrolizumab immunotherapy in patients with metastatic non-small cell lung cancer. Pembrolizumab works by blocking a molecule called PD-1 that shuts down the immune response. Blocking PD-1 can allow the immune system to detect and attack cancer cells. Guadecitabine and mocetinostat are “epigenetic therapies” that work on certain genes that may be turned on or off in cancer. Pembrolizumab is given intravenously (by vein). Guadecitabine is given by subcutaneous (under the skin) injection, and mocetinostat is taken orally (by mouth).
August 4, 2017 - July 31, 2020
Memorial Sloan Kettering
Matthew Hellman, MD
Hossein Borghaei, MS, DO
888-369-2427 or 215-214-4297
Jarushka Naidoo, MBBCh
Sign up for the latest lung health news sent right to your inbox.
Join more than 500,000 people who receive research updates, inspiring stories, health information and more.